The addition of tyrosine kinase inhibitor (TKI), Midostaurin, to standard chemotherapy protocol for AML led to significantly longer overall survival (OS) and event-free survival (EFS) in three FLT3 subgroups: FLT3-TKD, FLT3-ITD low and FLT3-ITD high AR (RATIFY-NCT00651261) (12). The gene discussed is FLT3; the disease is acute myeloid leukemia.